×
MAQTOX Partners with Telomir Pharmaceuticals to Unveil Telomir-1 Data at Singapore Longevity Conference

MAQTOX Partners with Telomir Pharmaceuticals to Unveil Telomir-1 Data at Singapore Longevity Conference

MAQTOX, a global leader in drug discovery and development, in partnership with Telomir Pharmaceuticals, showcased groundbreaking pre-clinical data on Telomir-1 at the NUHS Centre for Healthy Longevity Conference 2024 in Singapore. This high-profile event brought together some of the most renowned experts in the field of aging and longevity science, marking a significant milestone in the quest to extend human healthspan and combat age-related conditions.

Telomir-1, a novel compound developed by Telomir Pharmaceuticals, has demonstrated the potential to extend telomere length—a critical factor in cellular aging. Telomeres, the protective caps at the ends of chromosomes, naturally shorten as cells divide, contributing to aging and the onset of various age-related diseases. Telomir-1’s ability to reverse this process could represent a paradigm shift in how we approach the biology of aging.

Key Findings of the Study

The data presented at the conference highlighted Telomir-1's efficacy in increasing telomere length across three significant human cell lines:

  • MRC-5 Fetal Lung Fibroblasts: Essential for studying cellular aging and tissue regeneration.
  • Human Umbilical Endothelial Cells (HUVEC): Critical for vascular health and inflammation studies.
  • Mesenchymal Stem Cells (MSC): Widely known for their regenerative properties and therapeutic applications.

Dr. Danielle R. Baker, Ph.D., a leading scientist at MAQTOX, presented these findings in her poster titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains.” The study revealed that Telomir-1 not only successfully increased telomere length but also improved cell viability, paving the way for potential applications in treating age-related inflammatory conditions such as arthritis, cardiovascular diseases, and neurodegenerative disorders.

A Collaborative Effort for Global Impact

Chris Chapman, MD, Chairman and CEO of Telomir Pharmaceuticals, expressed his excitement about this collaboration:
"The data presented at this conference underscores the transformative potential of Telomir-1. If proven safe and effective in extending telomeres in human trials, it could redefine aging and open up new possibilities for prolonging healthy living."

This partnership between MAQTOX and Telomir Pharmaceuticals exemplifies the synergy between innovative drug development and cutting-edge research in the field of longevity. Together, the companies are setting new standards in how age-related conditions can be addressed with precision and efficacy.

The NUHS Centre for Healthy Longevity Conference 2024

Held in Singapore, this prestigious conference served as a platform for scientists, clinicians, and industry leaders to discuss advancements in aging research and healthcare innovation. The presentation of Telomir-1’s data was one of the conference's highlights, garnering significant attention and sparking discussions about its potential to address global health challenges associated with aging populations.

Looking Ahead

MAQTOX and Telomir Pharmaceuticals are committed to advancing Telomir-1 into clinical trials, ensuring rigorous safety and efficacy evaluations. The companies aim to expand their research collaborations with global partners, emphasizing a shared vision to improve human longevity and quality of life.

As the field of longevity science continues to gain momentum, MAQTOX’s partnership with Telomir Pharmaceuticals places them at the forefront of this transformative era. The promising results of Telomir-1 mark the beginning of a new chapter in healthcare, one that could potentially redefine how we age and inspire hope for healthier, longer lives.

About MAQTOX
MAQTOX is a leading provider of innovative drug discovery and development solutions, dedicated to transforming healthcare through cutting-edge research and collaborative partnerships. With a focus on addressing critical global health challenges, MAQTOX combines scientific excellence with a commitment to delivering impactful results.